Abstract: The present invention relates to the use of glial fibrillary acidic protein (GFAP) as a diagnostic marker for intracerebral hemorrhage. The invention especially relates to methods for the early detection of intracerebral hemorrhage. Such early and rapid detection can be performed rapidly e.g. by a test strip format assay. GFAP can be used as a stand-alone marker or in combination with one or more other markers.

Abstract: The present disclosure provides anti-bed bug monoclonal antibodies and antigen-binding fragments thereof as well as compositions and kits comprising the same. The present disclosure also provides methods of making monoclonal antibodies and antigen-binding fragments thereof and methods of using the same to detect bed bugs.

Abstract: The present invention relates to a cluster for the detection of an analyte, said cluster comprising a plurality of visually detectable colored particles and a plurality of luminescent particles, wherein (i) the particles are bound to each other, and (ii) at least one binding partner of an analyte is bound to the colored particles and/or the luminescent particles.

Abstract: Methods and devices are provided herein for identifying a cell population comprising an effector cell that exerts an extracellular effect. In one embodiment the method comprises retaining in a microreactor a cell population comprising one or more effector cells, wherein the contents of the microreactor further comprise a readout particle population comprising one or more readout particles, incubating the cell population and the readout particle population within the microreactor, assaying the cell population for the presence of the extracellular effect, wherein the readout particle population or subpopulation thereof provides a direct or indirect readout of the extracellular effect, and determining, based on the results of the assaying step, whether one or more effector cells within the cell population exerts the extracellular effect on the readout particle. If an extracellular effect is measured, the cell population is recovered for further analysis to determine the cell or cells responsible for the effect.

Abstract: The present invention relates to an immunoassay method for the detection of Chromogranin A (or fragment(s) thereof) comprising the steps of contacting a sample suspected of comprising Chromogranin A with a first antibody or an antigen-binding fragment or derivative thereof specific for Chromogranin A and a second antibody or an antigen-binding fragment or derivative thereof specific for Chromogranin A under conditions allowing for the formation of a ternary complex between Chromogranin A and the two antibodies or antigen-binding fragments or derivates thereof, and detecting the binding of the two antibodies or antigen-binding fragments or derivates thereof to Chromogranin A. Also provided are antibodies directed against amino acid residues 124 to 144 and 280 to 301 of Chromogranin A and their use in the immunoassay method.

Abstract: The present invention relates to an leucocyte antigen mediated microfluidic assay and a microfluidic device for analyzing a subjects' body fluids containing leucocytes to determine if the subject has been previously exposed to a predetermined antigen.

Abstract: Disclosed herein are systems, methods, and devices for monitoring and controlling bioprocess parameters. The systems and methods enable automated operation with real-time analysis of process conditions and analyte or biologic production.

Abstract: The present invention is directed to multiplexed fluorescence detection, including time-resolved fluorescence (TRF) detection. A combination of spectral and temporal differences in fluorescence emission and spectral differences in excitation is used to enhance the ability to separate signals in an assay from multiple fluorescent labels. Different classes of labels may be utilized, including upconversion phosphors as well as lanthanide chelates and transition metal chelates. The methods may be implemented in optical plate readers, including cartridge-based multi-mode readers.

Abstract: The disclosure provides improved materials and methods for optically clearing biological tissue that is subsequently used for deep tissue imaging analysis. Also provided is a description of a microscopic image acquisition methodology in which imagery of intact tissues are acquired to rapidly acquire microscopy data on a whole-organ scale to maximize cost effectiveness for biological microscopy and minimize time spent performing such analysis.

Abstract: The present invention provides a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The biological substance detection method according to the present invention is characterized in that the brightness retention rate of an immunostained part is in a range of 80% to 120% in relation to the brightness retention rate of a part stained for morphological observation when the fluorescent label used for the immunostaining is observed.

Abstract: Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.

Abstract: Compositions and methods for preparing a sample for immunological staining are provided. Compositions include kits comprising a first solution comprising a surfactant and a second solution comprising a chaotropic agent. Methods comprise contacting a sample, such as cells or tissues, with a first solution comprising a surfactant and then contacting the sample with a second solution comprising a chaotropic agent. The method does not require extreme heat for antigen retrieval and therefore, maintains the cellular morphology of the sample.

Abstract: Advantage is taken of macrolide antibiotics' complexation with free cholesterol to yield fluorescent complexes to determine the levels of free cholesterol, total cholesterol, or lecithin: cholesterol acyl transferase (LCAT) in serum or plasma or fractions thereof.

Abstract: The present invention relates to a multi-influenza detection kit comprising monoclonal antibodies and a method of detecting multiple influenza viruses using the kit. More specifically, the present invention relates to a multi-influenza detection kit comprising monoclonal antibodies that bind specifically to influenza type A, type B, subtype H1, subtype H3 and subtype H5, and to a method of detecting influenza viruses using the kit. The multi-influenza detection kit comprising monoclonal antibodies according to the present invention can simultaneously detect influenza types A and B and subtypes H1, H3 and H5, and thus is useful for the rapid and highly sensitive on-site detection and diagnosis of influenza.

Abstract: The application relates to a method for detecting a target in a sample suspected of containing the target. The method comprises contacting the sample and a first binding molecule attached to a magnetic particle with a second binding molecule attached to a solid support. The first binding molecule is capable of binding to the second binding molecule, and the target is capable of interfering with this binding. Magnetic force is applied to bring the magnetic particle into close proximity with the solid support. The number of magnetic particles bound to the solid support is detected.

Abstract: A cardiac troponin I ultra-sensitive detection reagent kit, a preparation method, and a detection method. The reagent kit comprises at least one first anti-cardiac troponin I antibody marked with a trace marker and at least one second anti-cardiac troponin I antibody coated on magnetic microspheres, the first anti-cardiac troponin I antibody and cardiac troponin I binding site being different from the second anti-cardiac troponin I antibody and cardiac troponin I binding site. The reagent kit may further comprise a diluent capable of significantly reducing non-specific binding in a detection process, so as to further increase the detection accuracy and sensitivity. The method using the reagent kit to detect cardiac troponin I sensitively and accurately detects the amount of cardiac troponin I in a sample, and provides more timely and reliable information for the early diagnosis and treatment of AMI.

Abstract: Provided is a testing device, including: a porous flow path member in which a flow path for flowing a sample is formed; and a resin layer provided at one position or a plurality of positions over the flow path member, wherein a reagent reactive with the sample is provided as a solid phase over a surface of the resin layer facing the flow path member.

Abstract: The present disclosure comprises a device and accompanying method for determining the presence or absence of Methicillin-resistant Staphylococcus aureus in a sample. The disclosure includes the following elements: (1) a lateral flow strip for microfluidic manipulation of a sample; (2) a cassette device for containing the lateral flow strip and enabling interface with a detection device; (3) a cassette handler; (4) a luminous reagent delivery device; and (5) an electromagnetic radiation detection device capable of converting chemiluminescent radiation from the lateral flow strip into an output for a user.

Abstract: The present invention relates to a beef-specific age determination marker containing the p21 protein, to an antibody specifically bound to bovine p21 protein, to a beef-specific age determination kit containing the antibody which is specifically bound to the bovine p21 protein, and to a method which involves detecting the bovine p21 protein through an antigen-antibody binding reaction using the antibody which is specifically bound to the bovine p21 protein serving as a beef-specific age determination marker in the muscle tissue of beef, so as to determine the age of the beef. According to the present invention, the p21 protein is significantly greatly expressed in the muscle tissue of beef, the age of which is lower than 30 months, and is hardly expressed in the muscle tissue of beef, the age of which is greater than 30 months, and thus can be valuably used as a beef-specific age determination marker.

Abstract: A method for measuring fibroblast growth factor-23 (FGF-23) in a sample, which comprise the following steps: (1) reacting, in an aqueous medium, FGF-23 in a sample with magnetic particles, a first antibody or a fragment thereof which binds to FGF-23, and a second antibody or a fragment thereof which binds to FGF-23, to form on the magnetic particles an immunocomplex comprising the first antibody or a fragment thereof which binds to FGF-23, FGF-23, and the second antibody or a fragment thereof which binds to FGF-23; (2) collecting the magnetic particles in the reaction mixture after step (1) by magnetic force, and separating the magnetic particles collected by magnetic force from the other components; and (3) measuring the immunocomplex on the magnetic particles separated in step (2). The present invention provides a method for measuring FGF-23 in a sample, which have a high sensitivity and have a wide measurement range.